FindTrial
Sign In

A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis

A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002169
Enrollment
Unknown
Registered
2001-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytomegalovirus Retinitis, HIV Infections

Keywords

AIDS-Related Opportunistic Infections, Placebos, Antiviral Agents, Cytomegalovirus Retinitis, Treatment Outcome, Nelfinavir

Brief summary

The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.

Interventions

DRUGNelfinavir mesylate

Sponsors

Agouron Pharmaceuticals
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients must have: * HIV infection. * Newly diagnosed or first progression of CMV retinitis.

Exclusion criteria

Prior Medication: Excluded: Prior therapy (or less than 2 weeks) with protease inhibitor other than saquinavir.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026